IRLAB publishes interim report for the period January-March 2024

Gothenburg, Sweden, May 8, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company’s interim report for the period January-March 2024, has been published.

IRLAB Enters a Development Collaboration for IRL757 as a Novel Treatment for Apathy

IRLAB has received approval from the Swedish Medical Products Agency to conduct a Phase I study of the drug candidate IRL757